{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:33:47Z","timestamp":1791862427423,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The First Hospital, Jilin University Changchun, China General Program of the National Natural Science Foundation","award":["No. 81771299"],"award-info":[{"award-number":["No. 81771299"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10072-019-04063-3","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T17:03:31Z","timestamp":1567875811000},"page":"295-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barr\u00e9 syndrome"],"prefix":"10.1007","volume":"41","author":[{"given":"Chunrong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-347X","authenticated-orcid":false,"given":"Kangding","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,7]]},"reference":[{"issue":"7","key":"4063_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1586\/1744666X.2013.811119","volume":"9","author":"BR Wakerley","year":"2013","unstructured":"Wakerley BR, Yuki N (2013) Infectious and noninfectious triggers in Guillain-Barre syndrome. Expert Rev Clin Immunol 9(7):627\u2013639","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"4063_CR2","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1074\/mcp.M115.056036","volume":"15","author":"RH Ziganshin","year":"2016","unstructured":"Ziganshin RH, Ivanova OM, Lomakin YA, Belogurov AA Jr, Kovalchuk SI, Azarkin IV, Arapidi GP, Anikanov NA, Shender VO, Piradov MA, Suponeva NA, Vorobyeva AA, Gabibov AG, Ivanov VT, Govorun VM (2016) The pathogenesis of the demyelinating form of Guillain-Barre Syndrome (GBS): proteo-peptidomic and immunological profiling of physiological fluids. Mol Cell Proteomics 15(7):2366\u20132378","journal-title":"Mol Cell Proteomics"},{"issue":"5","key":"4063_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cytogfr.2013.05.005","volume":"24","author":"HL Zhang","year":"2013","unstructured":"Zhang HL, Zheng XY, Zhu J (2013) Th1\/Th2\/Th17\/Treg cytokines in Guillain-Barre syndrome and experimental autoimmune neuritis. Cytokine Growth Factor Rev 24(5):443\u2013453","journal-title":"Cytokine Growth Factor Rev"},{"issue":"53","key":"4063_CR4","doi-asserted-by":"publisher","first-page":"41921","DOI":"10.1074\/jbc.M110.164020","volume":"285","author":"R Ferreira","year":"2010","unstructured":"Ferreira R, Xapelli S, Santos T, Silva AP, Crist\u00f3v\u00e3o A, Cortes L, Malva JO (2010) Neuropeptide Y modulation of interleukin-1{beta} (IL-1{beta})-induced nitric oxide production in microglia. J Biol Chem 285(53):41921\u201341934","journal-title":"J Biol Chem"},{"issue":"6","key":"4063_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0143-4179(94)90058-2","volume":"27","author":"K Maeda","year":"1994","unstructured":"Maeda K, Yasuda M, Kaneda H, Maeda S, Yamadori A (1994) Cerebrospinal fluid (CSF) neuropeptide Y- and somatostatin-like immunoreactivities in man. Neuropeptides. 27(6):323\u2013332","journal-title":"Neuropeptides."},{"issue":"7","key":"4063_CR6","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.4049\/jimmunol.171.7.3451","volume":"171","author":"S Bedoui","year":"2003","unstructured":"Bedoui S, Miyake S, Lin Y, Miyamoto K, Oki S, Kawamura N, Beck-Sickinger A, von H\u00f6rsten S, Yamamura T (2003) Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol 171(7):3451\u20133458","journal-title":"J Immunol"},{"issue":"21","key":"4063_CR7","doi-asserted-by":"publisher","first-page":"12544","DOI":"10.1073\/pnas.95.21.12544","volume":"95","author":"M Levite","year":"1998","unstructured":"Levite M (1998) Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci U S A 95(21):12544\u201312549","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4063_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","volume":"2","author":"RA Hughes","year":"1978","unstructured":"Hughes RA, Newsom-Davis JM, Perkin GD et al (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2:750\u2013753","journal-title":"Lancet"},{"key":"4063_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, van der Mech\u00e9 FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome. Muscle Nerve 14:1103\u20131109","journal-title":"Muscle Nerve"},{"issue":"4","key":"4063_CR10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/0887-8994(96)00050-1","volume":"14","author":"RC Reisin","year":"1996","unstructured":"Reisin RC, Pociecha J, Rodriguez E, Massaro ME, Arroyo HA, Fejerman N (1996) Severe Guillain-Barre syndrome in childhood treated with human immune globulin. Pediatr Neurol 14(4):308\u2013312","journal-title":"Pediatr Neurol"},{"key":"4063_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fendo.2017.00178","volume":"8","author":"A Thorsell","year":"2017","unstructured":"Thorsell A, Mathe AA (2017) Neuropeptide Y in alcohol addiction and affective disorders. Front Endocrinol (Lausanne) 8:178","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"4063_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/apha.12445","volume":"213","author":"A Farzi","year":"2015","unstructured":"Farzi A, Reichmann F, Holzer P (2015) The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour. Acta Physiol (Oxf) 213(3):603\u2013627","journal-title":"Acta Physiol (Oxf)"},{"issue":"1\u20132","key":"4063_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000026321","volume":"5","author":"N Kawamura","year":"1998","unstructured":"Kawamura N, Tamura H, Obana S, Wenner M, Ishikawa T, Nakata A, Yamamoto H (1998) Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets. Neuroimmunomodulation 5(1\u20132):9\u201315","journal-title":"Neuroimmunomodulation"},{"issue":"28","key":"4063_CR14","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.2174\/138161210793292465","volume":"16","author":"E Gonzalez-Rey","year":"2010","unstructured":"Gonzalez-Rey E, Delgado-Maroto V, Souza Moreira L, Delgado M (2010) Neuropeptides as therapeutic approach to autoimmune diseases. Curr Pharm Des 16(28):3158\u20133172","journal-title":"Curr Pharm Des"},{"issue":"1\u20132","key":"4063_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jneuroim.2005.03.021","volume":"165","author":"M Puerto","year":"2005","unstructured":"Puerto M, Guayerbas N, Alvarez P, De la Fuente M (2005) Modulation of neuropeptide Y and norepinephrine on several leucocyte functions in adult, old and very old mice. J Neuroimmunol 165(1\u20132):33\u201340","journal-title":"J Neuroimmunol"},{"issue":"1","key":"4063_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00726-011-1185-7","volume":"45","author":"M Dimitrijevi\u0107","year":"2013","unstructured":"Dimitrijevi\u0107 M, Stanojevi\u0107 S (2013) The intriguing mission of neuropeptide Y in the immune system. Amino Acids 45(1):41\u201353","journal-title":"Amino Acids"},{"issue":"3","key":"4063_CR17","doi-asserted-by":"publisher","first-page":"e57929","DOI":"10.1371\/journal.pone.0057929","volume":"8","author":"K Singer","year":"2013","unstructured":"Singer K, Morris DL, Oatmen KE, Wang T, DelProposto J, Mergian T, Cho KW, Lumeng CN (2013) Neuropeptide Y is produced by adipose tissue macrophages and regulates obesity-induced inflammation. PLoS One 8(3):e57929","journal-title":"PLoS One"},{"issue":"10","key":"4063_CR18","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1177\/0269881109348171","volume":"24","author":"E Painsipp","year":"2010","unstructured":"Painsipp E, Herzog H, Holzer P (2010) Evidence from knockout mice that neuropeptide-Y Y2 and Y4 receptor signalling prevents long-term depression-like behaviour caused by immune challenge. J Psychopharmacol 24(10):1551\u20131560","journal-title":"J Psychopharmacol"},{"issue":"1\u20132","key":"4063_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0165-5728(03)00133-4","volume":"139","author":"K Myhr","year":"2003","unstructured":"Myhr K (2003) Interleukin-10 promoter polymorphisms in patients with Guillain-Barr\u00e9 syndrome. J Neuroimmunol 139(1\u20132):81\u201383","journal-title":"J Neuroimmunol"},{"issue":"3","key":"4063_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1212\/WNL.58.3.476","volume":"58","author":"ROV Press","year":"2002","unstructured":"Press ROV, Kouwenhoven M, Link H (2002) Non-T(H)1 cytokines are augmented systematically early in Guillain-Barr\u00e9 syndrome. Neurology 58(3):476\u2013478","journal-title":"Neurology"},{"issue":"1\u20132","key":"4063_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0165-5728(98)00053-8","volume":"87","author":"KIA Hohnoki","year":"1998","unstructured":"Hohnoki KIA, Koh CS (1998) Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha\/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. Neuroimmunol 87(1\u20132):27\u201332","journal-title":"Neuroimmunol"},{"issue":"4","key":"4063_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.51","volume":"68","author":"KKPK Nyati","year":"2011","unstructured":"Nyati KKPK, Rizwan A, Verma A, Paliwal VK (2011) TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome. Arch Neurol 68(4):445\u2013452","journal-title":"Arch Neurol"},{"issue":"4","key":"4063_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1750-3639.2002.tb00459.x","volume":"12","author":"LLJ Bao","year":"2002","unstructured":"Bao LLJ, van der Meide P, Sw Z, Ljunggren HG, Zhu J (2002) The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathol 12(4):420\u2013429","journal-title":"Brain Pathol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-019-04063-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-019-04063-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-019-04063-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T23:54:28Z","timestamp":1599350068000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-019-04063-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,7]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4063"],"URL":"https:\/\/doi.org\/10.1007\/s10072-019-04063-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,7]]},"assertion":[{"value":"7 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of the First Hospital of Jilin University, Changchun, China.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}